Understanding heart risks from cancer treatments
Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology
['FUNDING_P01'] · STANFORD UNIVERSITY · NIH-10935736
This study is looking at how the cancer drug ibrutinib can affect the heart, and it aims to find out why some people are more at risk for these side effects while also exploring ways to protect the heart during treatment, so patients can help improve future cancer therapies.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10935736 on ClinicalTrials.gov |
What this research studies
This research investigates how certain cancer drugs, particularly ibrutinib, can cause heart-related side effects. By using advanced models, including patient-derived cells, the team aims to identify genetic factors that make some individuals more susceptible to these side effects. Additionally, the research seeks to discover protective mechanisms that could help mitigate heart damage caused by these treatments. Patients may contribute to the development of a platform that tests the cardiotoxicity of new cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with ibrutinib or similar therapies and may be at risk for heart issues.
Not a fit: Patients who are not undergoing cancer treatment or those without a history of heart conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with fewer heart-related complications for patients.
How similar studies have performed: Previous research has shown promising results in understanding cardiotoxicity related to cancer therapies, indicating that this approach has potential for success.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, JOSEPH C. — STANFORD UNIVERSITY
- Study coordinator: WU, JOSEPH C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Cancer Patient, Cancers, Cardiac Diseases